Express Scripts Holding Co. would be unwilling to proceed with its planned acquisition of Medco Health Solutions Inc. if the Federal Trade Commission requires the spin-off of the company’s specialty drug division as a condition of allowing the transaction to proceed, Express Scripts CEO George Paz, affirmed at a Senate subcommittee hearing Dec. 7.
The hearing before the Senate Judiciary Committee’s Subcommittee on Antitrust, Competition Policy and Consumer Rights focused on the potential anticompetitive effect of Express Scripts’ proposed acquisition of Medco.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?